Global Information
회사소개 | 문의

골다공증 : 파이프라인 리뷰

Osteoporosis - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 232788
페이지 정보 영문 273 Pages
가격
US $ 2,000 ₩ 2,287,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,575,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,863,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


골다공증 : 파이프라인 리뷰 Osteoporosis - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 273 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

골다공증은 뼈의 양 감소에 의해 뼈의 강도가 약해져 골절이 쉽게 발생하는 질환입니다. 노화, 성별, 저체중, 성호르몬의 부족 또는 폐경, 흡연, 특정 약제에 의한 발증 위험이 있습니다. 증상은 척추 손상 및 압박 골절에 의한 요통, 신장 저하, 앞으로 구부린 자세, 쉽게 발생하는 골절 등이며, 예방 또는 치료로는 칼슘, 비타민 D 섭취, 운동, 치료제에 의한 치료를 들 수 있습니다.

골다공증 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

골다공증 - 개요

골다공증 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

골다공증 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

골다공증 치료제 개발에 참여하고 있는 기업

  • Addex Therapeutics Ltd
  • Alize Pharma SAS
  • Alvogen Korea Co Ltd
  • Amgen Inc
  • Amura Holdings Ltd
  • BiologicsMD Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Company
  • Cellmid Ltd
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corium International Inc
  • Critical Pharmaceuticals Ltd
  • Daiichi Sankyo Company Ltd
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzo Biochem Inc
  • F. Hoffmann-La Roche Ltd
  • Gador SA
  • GL Pharm Tech Corp
  • Glide Pharmaceutical Technologies Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Haoma Medica Ltd
  • Immunovo BV
  • Immunwork Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Kaken Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Ligand Pharmaceuticals Inc
  • Lotus Pharmaceutical Co Ltd
  • Lupin Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • NIBEC
  • Omeros Corp
  • Oncobiologics Inc
  • Osteologix Holdings Plc
  • Paras Biopharmaceuticals Finland Oy
  • Pfenex Inc
  • PhytoHealth Corp
  • R Pharm
  • Ribomic Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinil Pharmaceutical Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Terpenoid Therapeutics Inc
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Viking Therapeutics Inc
  • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Yooyoung Pharm Co Ltd
  • Zydus Cadila Healthcare Ltd

약제 개요

골다공증 - 휴지중인 프로젝트

골다공증 - 개발이 중지된 제품

골다공증 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

List of Tables

  • Number of Products under Development for Osteoporosis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2018
  • Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Amgen Inc, H2 2018
  • Osteoporosis - Pipeline by Asahi Kasei Corp, H2 2018
  • Osteoporosis - Pipeline by BiosanaPharma BV, H2 2018
  • Osteoporosis - Pipeline by Biosion Inc, H2 2018
  • Osteoporosis - Pipeline by Bone Biologics Corp, H2 2018
  • Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Osteoporosis - Pipeline by Cadila Healthcare Ltd, H2 2018
  • Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Corium International Inc, H2 2018
  • Osteoporosis - Pipeline by Daewon Pharm Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Eli Lilly and Co, H2 2018
  • Osteoporosis - Pipeline by EndoCeutics Inc, H2 2018
  • Osteoporosis - Pipeline by Entera Bio Ltd, H2 2018
  • Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2018
  • Osteoporosis - Pipeline by Enzene Biosciences Ltd, H2 2018
  • Osteoporosis - Pipeline by Enzo Biochem Inc, H2 2018
  • Osteoporosis - Pipeline by Evgen Pharma Plc, H2 2018
  • Osteoporosis - Pipeline by Gador SA, H2 2018
  • Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H2 2018
  • Osteoporosis - Pipeline by GL Pharm Tech Corp, H2 2018
  • Osteoporosis - Pipeline by GlycoNex Inc, H2 2018
  • Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Haoma Medica Ltd, H2 2018
  • Osteoporosis - Pipeline by Huons Global Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Immunwork Inc, H2 2018
  • Osteoporosis - Pipeline by Innovent Biologics Inc, H2 2018
  • Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, H2 2018
  • Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H2 2018
  • Osteoporosis - Pipeline by Ipsen SA, H2 2018
  • Osteoporosis - Pipeline by JHL Biotech Inc, H2 2018
  • Osteoporosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
  • Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2018
  • Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2018

List of Figures

  • Number of Products under Development for Osteoporosis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 6, 4, 21, 3, 56, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 12 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy:

>
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoporosis - Overview
  • Osteoporosis - Therapeutics Development
  • Osteoporosis - Therapeutics Assessment
  • Osteoporosis - Companies Involved in Therapeutics Development
  • Osteoporosis - Drug Profiles
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research